甲氨蝶呤治疗克罗恩病的研究进展

发布时间：2018-05-21 19:06

本文选题：甲氨蝶呤 + 克罗恩病　；参考：《中国药房》2017年06期

【摘要】：目的:为进一步合理使用甲氨蝶呤(MTX)治疗克罗恩病(CD)提供参考。方法:通过查阅国内外文献,就MTX的作用机制、临床疗效及不良反应相关研究进行归纳和综述。结果:MTX可能通过抑制T细胞的增殖,下调炎症介质表达,抑制炎症反应而发挥作用;MTX用于CD活动期和缓解期的疗效均显著,但剂量和疗程的选择有所不同;并且,其长期使用安全性较高。结论:甲氨蝶呤对于激素依赖/无效、对嘌呤类似物抵抗或生物制剂治疗失败的CD患者(包括儿童)而言是一种不错的选择,但应进一步探索其合适的使用剂量、给药途径等,并加强其安全性评价。
[Abstract]:Objective: to provide reference for the rational use of methotrexate (MTX) in the treatment of Crohn's disease. Methods: the mechanism, clinical efficacy and adverse reactions of MTX were summarized and summarized by consulting the literature at home and abroad. Results it was possible that the effects of TX on CD activity and remission were significant by inhibiting the proliferation of T cells, down-regulating the expression of inflammatory mediators and inhibiting inflammatory response, but the dose and course of treatment were different. Its long-term use safety is high. Conclusion: methotrexate is a good choice for CD patients (including children) who are dependent on hormone, resistant to purine analogue or failed in biological treatment, but we should further explore the appropriate dosage and route of administration of methotrexate. And strengthen its safety evaluation.
【作者单位】：上海交通大学医学院附属瑞金医院药剂科;
【基金】：上海市临床药学重点专科建设项目(No.沪卫计药政[2016]7、8号)
【分类号】：R574.62

【相似文献】